IP Library Granted Patent US 9,322,036
Granted Patent B2
US 9,322,036 · App. 14/289,459 · Granted Apr 26, 2016

Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression

Inventors: Trevor Collingwood (Richmond, CA); Gregory J. Cost (Richmond, CA)
Assignee: Sangamo BioSciences, Inc.
C12N15/87C07K14/4703C07K16/00C12N9/1051C12N15/85C12P21/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,322,036
App. No.
14/289,459
Granted
Apr 26, 2016
Kind
B2
Abstract

Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.

Claims (54)

1. A method of inactivating an endogenous cellular FUT8 gene in an isolated cell, the method comprising:

introducing, into an isolated cell, a first nucleic acid encoding a first polypeptide, wherein the first polypeptide comprises:

(a) a first zinc finger DNA-binding domain, wherein the DNA-binding domain comprises four or five zinc finger recognition regions ordered F1 to F4, F1 to F5 or F1 to F6 from N-terminus to C-terminus, and wherein F1 to F4, F1 to F5 or F1 to F6 comprise amino acid sequences selected from the group consisting of:

(i)

F1: QSSDLSR (SEQ ID NO: 9);

F2: TSGNLTR (SEQ ID NO: 10);

F3: RSDDLSK (SEQ ID NO: 11);

and

F4: DRSALAR (SEQ ID NO: 12);

(ii) 

F1: RSDVLSA (SEQ ID NO: 14);

F2: QNATRIN (SEQ ID NO: 15);

F3: DRSNLSR (SEQ ID NO: 16);

and

F4: RLDNRTA (SEQ ID NO: 17);

(iii)

F1: RSDNLRE (SEQ ID NO: 26);

F2: NNTQLIE (SEQ ID NO: 27);

F3: TSSILSR (SEQ ID NO: 28);

F4 RSDNLSA (SEQ ID NO: 29);

and

F5: RKDTRIT (SEQ ID NO: 30);

and

(iv) 

F1: RSDNLSV (SEQ ID NO: 19);

F2: QNATRIN (SEQ ID NO: 15);

F3: RSDNLST (SEQ ID NO: 20) 

or RSDHLSQ (SEQ ID NO: 24);

F4: QSATRTK (SEQ ID NO: 21);

F5 RSDNLSR (SEQ ID NO: 22);

and

F6: RNDNRKT (SEQ ID NO: 23);

and

(b) a first cleavage domain; such that the polypeptide is expressed in the cell, whereby the polypeptide binds to the target site and cleaves the FUT8 gene; and

introducing a nucleic acid encoding a second polypeptide, wherein the second polypeptide comprises:

(i) a second zinc finger DNA-binding domain that is engineered to bind to a second target site in the FUT8 gene; and

(ii) a second cleavage domain; such that the second polypeptide is expressed in the cell,

whereby the first and second polypeptides bind to their respective target sites, dimerize and cleave the FUT8 gene, thereby inactivating the FUT8 gene.

2. The method of claim 1 , wherein the first and second polypeptides are encoded by the same nucleic acid.

3. The method of claim 1 , wherein the first and second polypeptides are encoded by different nucleic acids.

4. The method of claim 1 , wherein the first or second cleavage domain is a wild-type FokI cleavage domain.

5. The method of claim 1 , wherein the first or second cleavage domain is an engineered FokI cleavage domain.

6. The method of claim 1 , further comprising introducing donor sequence into the cell such that the donor sequence is integrated into the inactivated FUT8 gene.

7. A method of producing a recombinant protein of interest in an isolated cell, the method comprising the steps of:

(a) providing an isolated cell comprising an endogenous FUT8 gene;

(b) inactivating the endogenous FUT8 gene of the isolated cell by the method of claim 1 ; and

(c) introducing an expression vector comprising a transgene, the transgene comprising a sequence encoding a protein of interest into the cell, thereby producing the recombinant protein.

8. The method of claim 7 , wherein the protein of interest comprises an antibody.

9. A cell or cell line in which Fut8 is partially or fully inactivated, wherein the cell or cell line is produced by

(a) inactivating Fut8 in a cell according to the method of claim 1 ; and

(b) culturing the cell under conditions suitable for generating a cell or cell line in which Fut8 is partially or fully inactivated.

10. The cell or cell line of claim 9 , wherein the cell is a mammalian cell or cell line selected from the group consisting of a COS cell, a CHO cell, a VERO cell, a MDCK cell, a WI38 cell, a V79 cell, a B14AF28-G3 cell, a BHK cell, a HaK cell, a NS0 cell, a SP2/0-Ag14 cell, a HeLa cell, an HEK293 cell, and a perC6 cell.

11. The cell or cell line of claim 9 , wherein one or more additional genes are partially or fully inactivated.

12. The cell or cell line of claim 11 , wherein dihydrofolate reducatase (DHFR) and glutamine synthetase (GS) have been inactivated.

Assignments (1)
CHANGE OF NAME Recorded Nov 6, 2017
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 044383/0799 →
Continuity (5)
Division 12931265 · Jan 7, 2011
Division 12218035 · Jul 10, 2008
Provisional Application 60959202 · Jul 12, 2007
Provisional Application 60993624 · Sep 13, 2007
Related Publication 20140273097A1 · Sep 18, 2014